Holen Sie sich die Stockscreener-App
7.24
1.63%
-0.12
Schlusskurs vom Vortag:
$7.36
Offen:
$7.32
24-Stunden-Volumen:
317.12K
Relative Volume:
0.90
Marktkapitalisierung:
$190.50M
Einnahmen:
$56.65M
Nettoeinkommen (Verlust:
$-53.31M
KGV:
-3.5417
EPS:
-2.0442
Netto-Cashflow:
$-40.75M
1W Leistung:
-7.30%
1M Leistung:
-16.69%
6M Leistung:
-28.25%
1J Leistung:
+15.84%
1-Tages-Spanne:
$7.19
$7.45
1-Wochen-Bereich:
$7.19
$8.48
52-Wochen-Spanne:
$4.2993
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Firmenname
Cvrx Inc
Sektor
Branche
Telefon
(763) 416-2850
Adresse
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
7.24 | 193.65M | 56.65M | -53.31M | -40.75M | -2.0442 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-01-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-11 | Bestätigt | Lake Street | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2024-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Lake Street | Buy |
| 2022-07-18 | Eingeleitet | Craig Hallum | Buy |
| 2021-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-26 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cvrx Inc Aktie (CVRX) Neueste Nachrichten
CVRx nominates Michael Dale to board of directors - Investing.com
Lawnwood Medical Center achieves milestone with 15th Barostim therapy, CVRx confirms - Traders Union
CVRx nominates Michael Dale to board of directors By Investing.com - Investing.com South Africa
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors - marketscreener.com
Press Release: CVRx Announces Nomination of Michael Dale for Election to the Board of Directors - Moomoo
CVRx (CVRX) details 2026 virtual meeting, board nominees and pay - Stock Titan
Behavioral Patterns of CVRX and Institutional Flows - Stock Traders Daily
CVRX Should I Buy - Intellectia AI
CVRx unveils Barostim session on neurohormonal targeting at ISHLT2026 - Traders Union
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
CVRX Maintained by Canaccord Genuity -- Price Target Steady at $10 - GuruFocus
CVRx (NASDAQ:CVRX) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
Lake Street Remains a Buy on CVRx (CVRX) - The Globe and Mail
A Quick Look at Today's Ratings for CVRx Inc(CVRX.US), With a Forecast Between $10 to $14 - 富途牛牛
Lake Street Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14 - 富途牛牛
William Blair reiterates CVRx stock rating on strong Q1 results By Investing.com - Investing.com Australia
William Blair reiterates CVRx stock rating on strong Q1 results - Investing.com
CVRx Reports 20% Revenue Growth and Improved Medicare Approval Rates in Preliminary Q1 2026 Results - Minichart
CVRx expects robust 20 percent revenue growth in preliminary Q1 results - Traders Union
CVRx Reports Strong Q1 Growth and Trial Progress - TipRanks
CVRx preliminary Q1 revenue rises 20%, gross margin improves - TradingView
CVRx (NASDAQ: CVRX) posts Q1 growth and advances BENEFIT-HF trial - Stock Titan
CVRx says Medicare approval rates improved as heart device sales rose - Stock Titan
Forecast Cut: Is CVRX a speculative investmentCPI Data & AI Based Buy and Sell Signals - baoquankhu1.vn
Bear Alert: Is CVRx Inc stock overvalued or fairly priced2026 Catalysts & Short-Term High Return Ideas - baoquankhu1.vn
CVRx, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
(CVRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Pharma News: Will CVRX benefit from government policyDay Trade & Reliable Price Breakout Alerts - baoquankhu1.vn
Analysis Recap: Can CVRx Inc weather a recession2026 Price Action Summary & Trade Opportunity Analysis - baoquankhu1.vn
CVRX Apr 2026 7.500 call (CVRX260417C00007500) Interactive Stock Chart - Yahoo! Finance Canada
CVRX Apr 2026 10.000 put (CVRX260417P00010000) Interactive Stock Chart - Yahoo! Finance Canada
CVRX Earnings History & Surprises | EPS & Revenue Results | CVRX INC (NASDAQ:CVRX) - ChartMill
CVRx, Inc. (NASDAQ:CVRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Patterns Watch: Is CVRX a speculative investmentPortfolio Profit Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sectors Review: Is CVRX a strong candidate for buy and holdInsider Buying & Technical Analysis for Trade Confirmation - baoquankhu1.vn
IMA,CVRX Volatility & Greeks - Finviz
How (CVRX) Movements Inform Risk Allocation Models - Stock Traders Daily
CVRx touts Barostim therapy as improving exercise capacity in heart failure beyond GDMT alone - Traders Union
SGP,CVRX Volatility & Greeks - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out | NDAQ:CVRX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (NASDAQ:CVRX) Q4 2025 earnings call transcript - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IMA,CVRX Dividends - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect - ACCESS Newswire
CVRx’s BENEFIT-HF Trial: New Heart Failure Study Sets Up a Key Catalyst for Investors - tipranks.com
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
CVRx Inc Stock (ISIN: US12674F1003) Gains Momentum on Heart Failure Device Adoption Amid Medtech Sec - AD HOC NEWS
Sentiment Review: Will CVRX benefit from government policy2026 Price Swings & Precise Buy Zone Identification - baoquankhu1.vn
Finanzdaten der Cvrx Inc-Aktie (CVRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):